Statements (29)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:activeIngredient |
amphetamine
|
| gptkbp:age |
adolescents
children |
| gptkbp:broadcastOn |
gptkb:Schedule_II_controlled_substance
|
| gptkbp:contraindication |
glaucoma
hyperthyroidism use with MAO inhibitors history of drug abuse advanced arteriosclerosis known hypersensitivity to amphetamines moderate to severe hypertension symptomatic cardiovascular disease |
| gptkbp:form |
extended-release oral suspension
|
| https://www.w3.org/2000/01/rdf-schema#label |
Dynavel XR
|
| gptkbp:indication |
gptkb:attention_deficit_hyperactivity_disorder
|
| gptkbp:manufacturer |
gptkb:Tris_Pharma
|
| gptkbp:regulates |
approved
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
abdominal pain
weight loss increased heart rate insomnia irritability decreased appetite increased blood pressure |
| gptkbp:bfsParent |
gptkb:Amphetamine
gptkb:amphetamine |
| gptkbp:bfsLayer |
6
|